The government is now operating in accordance with the Guidance on Caretaker Conventions, pending the outcome of the 2025 federal election.
HEMGENIX (CSL Behring Australia Pty Ltd)
Product name
HEMGENIX
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
213 (255 working days)
Active ingredients
etranacogene dezaparvovec
Registration type
NCE/NBE
Indication
This medicine has provisional approval in Australia.
HEMGENIX® is an adeno-associated virus vector-based gene therapy indicated for treatment of adults with haemophilia B (congenital factor IX deficiency), without a history of factor IX inhibitors, who:
- currently use factor IX prophylaxis therapy, or
- have current or historical life-threatening haemorrhage, or repeated, serious spontaneous bleeding episodes.
The decision to approve this indication has been made on the basis of short-term efficacy and safety data from the clinical trial program. Continued approval of this indication depends on confirmation of longer-term benefit from ongoing clinical trials.